Relay Therapeutics, Inc. (RLAY)

NGM – Real Time Price. Currency in USD

19.99

0.00 (0.00%)

Market open: Aug 12, 2026, 11:07 AM EDT

20.17

+0.18 (0.90%)

Previous after-hours: Aug 11, 2026, 7:34 PM EDT

Stock details

Previous close: 19.77$
Day's range: 18.68 - 19.85$
52-week range: 3.15 - 20.79$
Volume: 2 315 219
Average volume: 2 264 053
Beta: 1.58
EPS (TTM): -1.57
PE ratio (TTM): N/A
Forward P/E: N/A
Market cap: 4 332 430 167
Shares outstanding: 219 141 637
Dividend yield: N/A
Next earnings date: 2026-11-11
Sector: Healthcare
Industry: Biotechnology

About the company

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-2608, a pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor that is in clinical development for the trea... read more

CEO: Sanjiv Patel
Country: United States
IPO Date: 2020-07-16
Employees: 192
Fiscal Year End: January - December
Website: https://www.relaytx.com

Revenue Breakdown

Small Molecule Precision Medicine / 100.00%

News

No Data

There are no news for this stock.

Chart: RLAY

Loading Chart...

Overall Score

1.9 / 1019%

Octagon View

Strength & Weakness

Cash reserves $0.0 barely cover the upcoming debt maturities $0.0

Total current assets $0.0 are just enough to cover Total current liabilities $0.0, indicating tight liquidity

Debt-to-equity ratio (0.0) is near the industry average, reflecting balanced leverage

Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns

Financial Strength

NAME	RATIO	INDUSTRY	SCORE
Current ratio	N/A	6.05	1.0
Quick ratio	N/A	5.63	1.0
Debt to Equity	N/A	0.30	1.0
Debt to Assets	N/A	1.04	1.0
Interest coverage	N/A	-16.91	1.0
Weighted average score			1.0

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)

Values in USD (B=Billions, M=Millions, K=Thousands)

METRIC	2022	2023	2024	2025	TTM
Total Revenue	1M	26M	10M	15M	10M
Gross Profit	-3M	20M	5M	12M	8M
Operating Income	-311M	-379M	-386M	-303M	-310M
Net Income	-291M	-342M	-338M	-276M	-286M
EBITDA	-307M	-374M	-380M	-299M	-218M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAME	RATIO	INDUSTRY	SCORE
Gross margin %	N/A	-11.73	1.0
Operating margin %	-25949.71	-24.60	1.0
Net margin %	-23916.29	-172.20	1.0
EBITDA margin %	N/A	-201.27	1.0
Cash flow margin %	N/A	-156.39	1.0
Weighted average score			1.0

Net Margin

Effectiveness

NAME	RATIO	INDUSTRY	SCORE
ROA	-36.09	-57.97	1.0
ROE	-39.76	-63.56	1.0
ROIC	-40.01	-42.57	1.0
ROCE	-11.39	-71.10	1.0
Weighted average score			1.0

Estimated EPS vs Actual EPS

Forecast

NAME	REVENUE GROWTH	EPS GROWTH	SCORE
Current quarter	N/A	7.32	3.0
Next quarter	6.49	-18.17	3.0
Current year	-27.16	0.6	1.5
Next year	39.92	-4.58	5.5
Weighted average score			3.3

Analyst Rating

Growth

NAME	REVENUE	NET INCOME	EPS	FCF	SCORE
Q/Q	-88.32	-14.2	0	-13.91	1.0
Y/Y	-48.29	-18.93	0	30.55	3.3
3y average	580.81	0.56	13.16	-1.33	5.3
5y average	318.34	-114.47	20.19	-36.97	5.5
Weighted average score					3.8

Revenue Growth Rate vs. Industry

Valuation

NAME	RATIO	INDUSTRY	SCORE
P/E	17.31	-5.25	6.0
PEG (5yr expected)	N/A	0.27	1.0
P/S	347.96	64.66	1.6
P/B	4.87	2.96	3.2
Weighted average score			3.0

DCF Model

Data not available

Insufficient positive free cash flow for DCF analysis

Dividend

NAME	CURRENT	INDUSTRY	SCORE
Dividend yield	0.00	N/A	1.0
Payout ratio	0.00	N/A	1.0
5-year dividend growth rate	N/A	N/A	1.0
Years of dividend increase	N/A	N/A	1.0
Weighted average score			1.0

Fair Value

Data not available

Insufficient positive free cash flow for DCF analysis

Economic Moat

NAME	SCALE	SCORE
Market share	None	1.0
Intangible assets	None	1.0
Switching costs	None	1.0
Network effect	None	1.0
Economies of scale	None	1.0
Weighted average score		1.0

About the company

CEO

Sanjiv Patel

Country

United States

IPO Date

2020-07-16

Employees

192

Fiscal Year End

January - December

Website

https://www.relaytx.com

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Current ratio

N/A

6.05

1.0

Quick ratio

N/A

5.63

1.0

Debt to Equity

N/A

0.30

1.0

Debt to Assets

N/A

1.04

1.0

Interest coverage

N/A

-16.91

1.0

Weighted average score

1.0

METRIC

2022

2023

2024

2025

TTM

Total Revenue

26M

10M

15M

10M

Gross Profit

-3M

20M

12M

Operating Income

-311M

-379M

-386M

-303M

-310M

Net Income

-291M

-342M

-338M

-276M

-286M

EBITDA

-307M

-374M

-380M

-299M

-218M

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

Gross margin %

N/A

-11.73

1.0

Operating margin %

-25949.71

-24.60

1.0

Net margin %

-23916.29

-172.20

1.0

EBITDA margin %

N/A

-201.27

1.0

Cash flow margin %

N/A

-156.39

1.0

Weighted average score

1.0

NAME

RATIO

INDUSTRY

5Y TREND

SCORE

ROA

-36.09

-57.97

1.0

ROE

-39.76

-63.56

1.0

ROIC

-40.01

-42.57

1.0

ROCE

-11.39

-71.10

1.0

Weighted average score

1.0

NAME

REVENUE GROWTH

EPS GROWTH

SCORE

Current quarter

N/A

7.32

3.0

Next quarter

6.49

-18.17

3.0

Current year

-27.16

0.6

1.5

Next year

39.92

-4.58

5.5

Weighted average score

3.3

NAME

REVENUE

NET INCOME

EPS

FCF

SCORE

Q/Q

-88.32

-14.2

-13.91

1.0

Y/Y

-48.29

-18.93

30.55

3.3

3y average

580.81

0.56

13.16

-1.33

5.3

5y average

318.34

-114.47

20.19

-36.97

5.5

Weighted average score

3.8

NAME

RATIO

INDUSTRY

5Q TREND

SCORE

P/E

17.31

-5.25

6.0

PEG (5yr expected)

N/A

0.27

1.0

P/S

347.96

64.66

1.6

P/B

4.87

2.96

3.2

Weighted average score

3.0

NAME

CURRENT

INDUSTRY

SCORE

Dividend yield

0.00

N/A

1.0

Payout ratio

0.00

N/A

1.0

5-year dividend growth rate

N/A

1.0

Years of dividend increase

N/A

1.0

Weighted average score

1.0

NAME

SCALE

SCORE

Market share

None

1.0

Intangible assets

None

1.0

Switching costs

None

1.0

Network effect

None

1.0

Economies of scale

None

1.0

Weighted average score

1.0

Search stocks

Relay Therapeutics, Inc. (RLAY)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Relay Therapeutics, Inc. (RLAY)

Stock details

About the company

Revenue Breakdown

News

Chart: RLAY

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Data not available

Dividend

Fair Value

Data not available

Economic Moat

Stock details

About the company

Revenue Breakdown

News

Chart: RLAY

Overall Score

Octagon View

Strength & Weakness

Financial Strength

Debt to Assets

Financial

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

Net Margin

Effectiveness

Estimated EPS vs Actual EPS

Forecast

Analyst Rating

Growth

Revenue Growth Rate vs. Industry

Valuation

DCF Model

Data not available

Dividend

Fair Value

Data not available

Economic Moat